Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir Monotherapy in HIV-1
NCT00708110Phase 2Completed
- Sponsor
- ViiV Healthcare
- Start
- Jun 2008
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by ViiV Healthcare. Primary endpoints: Change From Baseline in Plasma HIV-1 RNA at Day 11, Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time at Day 1 and 2 more. Started Jun 2008; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00708110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00708110.